JACKSONVILLE, Fla.--(BUSINESS WIRE)--Today, the American Association of Clinical Endocrinologists (AACE) released new Guidelines for the Management of Dyslipidemia and Prevention of Atherosclerosis on its website, which will be published in the March/April edition of Endocrine Practice, the association’s peer-reviewed medical journal.
These new guidelines have been updated to include an expanded and comprehensive approach to the treatment and management of lipid disorders.
“People with obesity, diabetes and other metabolic conditions have complex lipids disorders leading to atherosclerosis. The new comprehensive AACE guidelines bring needed contemporary recommendations to prevent and manage complications leading to cardiovascular disease,” said AACE President Yehuda Handelsman MD, FACP, FACE, FNLA.
The updates to these evidence-based guidelines are built on extensive data accumulated since the previous version and are complete with more than 600 references. Expanded sections of the guidelines include inflammatory markers and their appropriate use, dyslipidemia in diabetes, apolipoproteins, pediatric dyslipidemia, lipid disorders in women, recommendations for medical nutrition therapy and physical activity, and cost effectiveness of lipid-lowering therapy. The guidelines also extensively cover global risk assessment, recent statin trials, statin therapy, and issues related to fibrates and niacin, as well as offer clear recommendations for lipid management goals in people at risk for cardiovascular disease.
“These guidelines serve as a tool to help clinicians identify patients who need therapy and guide clinicians to select the appropriate therapy for each patient,” said Paul Jellinger, MD, MACE, chair of the AACE Task Force on Lipid Guidelines.
The guidelines complement and expand the guidelines issued by the National Cholesterol Education Program (NCEP), proposing even more stringent standards for the highest risk patients. For example, the 2004 updated recommendations of the NCEP suggested that for patients at very high risk a therapeutic option is an LDL of less than 70 mg/dL. The new AACE guidelines recommend that LDL less than 70 mg/dL should apply to all patients with established coronary artery disease (CAD). Furthermore, the AACE guidelines highlight the value of non-HDL and apolipoprotein B in guiding lipid-lowering therapy.
The new AACE Guidelines for the Management of Dyslipidemia and Prevention of Atherosclerosis, as published in the March/April edition of Endocrine Practice can be found here.
The American Association of Clinical Endocrinologists (AACE)
The American Association of Clinical Endocrinologists (AACE) represents more than 6,500 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. The majority of AACE members are certified in Endocrinology and Metabolism and concentrate on the treatment of patients with endocrine and metabolic disorders including diabetes, thyroid disorders, osteoporosis, growth hormone deficiency, cholesterol disorders, hypertension and obesity. For more information about AACE, visit the AACE website at www.aace.com, become a fan on Facebook at www.facebook.com/theaace or follow AACE on Twitter at www.twitter.com/theaace.